Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 137Breast Neoplasms 10Neoplasm Metastasis 8Neoplasms 5Bulbo-Spinal Atrophy, X-Linked 5Triple Negative Breast Neoplasms 4Salivary Gland Neoplasms 2Prostate Adenocarcinoma 2Osteoporosis 2Lower Urinary Tract Symptoms 2Hirsutism 2Thrombocytosis 1Stage I Prostate Adenocarcinoma AJCC v7 1Stage I Prostate Adenocarcinoma 1Sexual Dysfunction, Physiological 1Recurrence 1Primary Myelofibrosis 1Primary Dysautonomias 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Paget Disease, Extramammary 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Non Castrate Metastatic Prostate Cancer 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Metformin 8Progesterone 6Spironolactone 4drospirenone and ethinyl estradiol combination 3Inositol 3Ethinyl Estradiol 3salicylsalicylic acid 2Sugars 2Folic Acid 2Flutamide 2Estradiol 2Cyproterone Acetate 2Clomiphene 2maltodextrin 1licogliflozin 1bicalutamide 1Yoga 1Topiramate 1Thioctic Acid 1Sodium Salicylate 1Phlebotomy 1Ovidrel 1Magnesium 1Lactalbumin 1Inulin 1Glycoprotein Hormones, alpha Subunit 1Estrogens 1Doxycycline 1Dexamethasone 1Cyproterone acetate, ethinyl estradiol drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hyperandrogenism × bicalutamide × Clear all
NCT05647356 2022-12-12

REFUEL PCOS

Royal College of Surgeons, Ireland

Phase NA Unknown
16 enrolled

Metabolic Diseases, Polycystic Ovary Syndrome, Hyperandrogenism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡